Repligen Co. (NASDAQ:RGEN) Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund raised its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 14.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 567,044 shares of the biotechnology company's stock after purchasing an additional 71,274 shares during the quarter. New York State Common Retirement Fund owned 1.01% of Repligen worth $84,387,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Toronto Dominion Bank lifted its position in shares of Repligen by 1.5% during the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after purchasing an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Repligen by 1.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock worth $982,000 after purchasing an additional 89 shares during the last quarter. Ballentine Partners LLC raised its holdings in shares of Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock valued at $269,000 after acquiring an additional 105 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after acquiring an additional 106 shares in the last quarter. Finally, CWM LLC raised its holdings in shares of Repligen by 36.3% in the third quarter. CWM LLC now owns 428 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 114 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. UBS Group decreased their price objective on Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, July 31st. Royal Bank of Canada restated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a report on Wednesday, July 31st. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective for the company. Finally, Benchmark reiterated a "hold" rating on shares of Repligen in a report on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $190.25.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the business's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Stock Up 3.2 %

Repligen stock traded up $4.34 during trading hours on Friday, reaching $138.61. The stock had a trading volume of 463,879 shares, compared to its average volume of 549,693. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a market cap of $7.76 billion, a price-to-earnings ratio of -3,464.38, a PEG ratio of 3.85 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The business's 50 day moving average price is $142.04 and its 200-day moving average price is $145.83.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts' consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. During the same quarter in the previous year, the firm earned $0.53 earnings per share. The company's revenue was down 3.2% on a year-over-year basis. Sell-side analysts anticipate that Repligen Co. will post 1.45 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.